More and more decisions will center on the ability to molecularly characterize a disease. So the molecular diagnostic laboratory will have a pivotal role. What does that look like? Will we be able to maintain an environment where we have academic laboratories doing a good chunk of innovation and development that then can get translated into either reference laboratories or tests being done at local laboratories within the academic core and even community hospitals? The ecosystem that exists now encourages innovation to happen quickly and get those tests quickly into the hands of the clinical laboratories and make them accessible to patients. So the question is can we maintain this ecosystem when we overlay regulatory pressures, and financial or reimbursement pressures.